NCT00436956View on ClinicalTrials.gov

AZD2171 to Treat Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

October 16, 2006

Primary Completion Date

February 1, 2010

Study Completion Date

February 5, 2014

Conditions
Prostate Cancer
Interventions
PROCEDURE

Magnetic Resonance Imaging (DCE-MRI)

Scans evaluate tumor tissue and blood flow.

DRUG

AZD2171

20 mg oral daily for 28 days

DRUG

Prednisone

10mg orally daily in combination with AZD2171 20mg daily.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00436956 - AZD2171 to Treat Prostate Cancer | Biotech Hunter | Biotech Hunter